MX2021010283A - Composiciones de anticuerpo anti-cd6 y metodos para tratar lupus. - Google Patents

Composiciones de anticuerpo anti-cd6 y metodos para tratar lupus.

Info

Publication number
MX2021010283A
MX2021010283A MX2021010283A MX2021010283A MX2021010283A MX 2021010283 A MX2021010283 A MX 2021010283A MX 2021010283 A MX2021010283 A MX 2021010283A MX 2021010283 A MX2021010283 A MX 2021010283A MX 2021010283 A MX2021010283 A MX 2021010283A
Authority
MX
Mexico
Prior art keywords
methods
alcam
inhibitors
antibody compositions
present disclosure
Prior art date
Application number
MX2021010283A
Other languages
English (en)
Spanish (es)
Inventor
Stephen Connelly
Krishna Polu
Chandra Mohan
Original Assignee
Equillium Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Equillium Inc filed Critical Equillium Inc
Publication of MX2021010283A publication Critical patent/MX2021010283A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2021010283A 2019-02-26 2020-02-26 Composiciones de anticuerpo anti-cd6 y metodos para tratar lupus. MX2021010283A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962810628P 2019-02-26 2019-02-26
US201962933294P 2019-11-08 2019-11-08
PCT/US2020/019990 WO2020176682A1 (en) 2019-02-26 2020-02-26 Anti-cd6 antibody compositions and methods for treating lupus

Publications (1)

Publication Number Publication Date
MX2021010283A true MX2021010283A (es) 2021-09-30

Family

ID=70009403

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021010283A MX2021010283A (es) 2019-02-26 2020-02-26 Composiciones de anticuerpo anti-cd6 y metodos para tratar lupus.

Country Status (12)

Country Link
US (1) US20220143140A1 (cg-RX-API-DMAC7.html)
EP (1) EP3930751A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022521973A (cg-RX-API-DMAC7.html)
CN (1) CN113490511B (cg-RX-API-DMAC7.html)
AU (1) AU2020229830A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021016967A2 (cg-RX-API-DMAC7.html)
CA (1) CA3131299A1 (cg-RX-API-DMAC7.html)
MX (1) MX2021010283A (cg-RX-API-DMAC7.html)
PH (1) PH12021551994A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202109118XA (cg-RX-API-DMAC7.html)
WO (1) WO2020176682A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202107077B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2993186T (pt) 2008-03-14 2019-11-29 Biocon Ltd Anticorpo monoclonal e um método do mesmo
IL303290A (en) * 2020-12-04 2023-07-01 Equillium Inc Methods of selectively targeting cd6 high cells and decreasing activity of t eff cells
EP4533094A4 (en) * 2022-05-25 2026-05-06 Univ Houston System METHODS AND SYSTEMS FOR RISK STRATIFICATION AND BLADDER CANCER MANAGEMENT
TWI869873B (zh) * 2023-06-05 2025-01-11 中國醫藥大學 一種檢測一個體罹患單純復發性風濕病的方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998172A (en) * 1993-11-02 1999-12-07 Duke University Anti-CD6 ligand antibodies
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
CU22584A1 (es) 1995-11-17 1999-11-03 Centro Inmunologia Molecular Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis
AU747898B2 (en) * 1997-03-03 2002-05-30 Bristol-Myers Squibb Company Monoclonal antibodies to human CD6
MY154819A (en) 2006-12-26 2015-07-31 Centro Inmunologia Molecular Pharmaceutical compositions with capacity to induce adoptosis in tumor cells for the diagnosis and treatment of the b-cell chroniclymphocytic leukemia
PT2993186T (pt) * 2008-03-14 2019-11-29 Biocon Ltd Anticorpo monoclonal e um método do mesmo
WO2012133047A1 (ja) * 2011-03-25 2012-10-04 コニカミノルタエムジー株式会社 免疫組織染色法、およびこれを用いた抗体医薬の有効性を判定する方法
EP2726879B1 (en) * 2011-07-01 2022-10-19 Beckman Coulter, Inc. Requlatory t cells and methods of identifying and isolating them using cd6 -expression or the combination of cd4, cd25 and cd127
CA2866612C (en) * 2012-03-08 2018-01-16 Halozyme, Inc. Conditionally active ph-dependent cetuximab variant anti-epidermal growth factor receptor antibodies and method of use thereof
US10620201B2 (en) * 2014-01-20 2020-04-14 Pad 4 Di Maria Adele Silvia Denegri S.A.S. In vitro method for predicting, diagnosing and monitoring in therapeutic follow up lupus nephritis
SG11201808625QA (en) * 2016-04-04 2018-10-30 Chemocentryx Inc SOLUBLE C5aR ANTAGONISTS
WO2017214452A1 (en) * 2016-06-08 2017-12-14 Xencor, Inc. Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b
KR102514528B1 (ko) * 2016-10-21 2023-03-27 바이오콘 리미티드 루푸스 치료를 위한 단일클론항체 및 이의 치료방법

Also Published As

Publication number Publication date
PH12021551994A1 (en) 2022-08-15
SG11202109118XA (en) 2021-09-29
JP2022521973A (ja) 2022-04-13
BR112021016967A2 (pt) 2021-11-23
ZA202107077B (en) 2023-07-26
CA3131299A1 (en) 2020-09-03
US20220143140A1 (en) 2022-05-12
WO2020176682A1 (en) 2020-09-03
AU2020229830A1 (en) 2021-09-16
CN113490511B (zh) 2024-07-09
EP3930751A1 (en) 2022-01-05
CN113490511A (zh) 2021-10-08

Similar Documents

Publication Publication Date Title
PH12021551994A1 (en) Anti-cd6 antibody compositions and methods for treating lupus
Spengler et al. Release of active peptidyl arginine deiminases by neutrophils can explain production of extracellular citrullinated autoantigens in rheumatoid arthritis synovial fluid
Ayllon et al. Systems biology of tissue-specific response to Anaplasma phagocytophilum reveals differentiated apoptosis in the tick vector Ixodes scapularis
Badot et al. Serum soluble interleukin 7 receptor is strongly associated with lupus nephritis in patients with systemic lupus erythematosus
Turankar et al. Comparative evaluation of PCR amplification of RLEP, 16S rRNA, rpoT and Sod A gene targets for detection of M. leprae DNA from clinical and environmental samples
JOP20170041B1 (ar) اجسام مضادة ضد vista (b7h5)
BRPI0708101B1 (pt) anticorpo, ou seu fragmento de ligação a antígeno, que especificamente se liga a il-22, composição farmacêutica, ácido nucléico isolado, vetor de expressão, célula hospedeira, método de produção do mesmo e kit diagnóstico
BR112022003335A2 (pt) Conjugados de il-2 e métodos de uso para tratar doenças autoimunes
CL2007003649A1 (es) Un conjugado de molecula asociado a anticuerpo monoclonal humano anti-cd70; composicion que comprende al conjugado de molecula asociado a anticuerpo; metodo de inhibicion del crecimiento de celulas tumorales que expresan cd70.
EA202090265A1 (ru) Композиции, способы и/или наборы, содержащие рекомбинантный внеклеточный домен cd38 человека
EA201590630A1 (ru) Способы лечения и диагностики, связанные с лизилоксидазоподобным белком 2 (loxl2)
EA200971131A1 (ru) Биомаркеры для прогнозирования чувствительности или отсутствия чувствительности к анти-фно агентам
BR112013028779B8 (pt) proteína de ligação de antígeno ou imunoconjugado, imunoconjugado, composição farmacêutica, e, uso de uma composição
EA201900561A1 (ru) Конъюгаты циклодекстрин-белок-лекарственное средство
EA200801679A1 (ru) Композиции и способы применения антител к dickkopf-1 и/или -4
Vora et al. Ticks elicit variable fibrinogenolytic activities upon feeding on hosts with different immune backgrounds
ES2657414T3 (es) Uso de la lactoferrina en el diagnóstico o el pronóstico de la enfermedad de Alzheimer
WO2020041360A8 (en) Dbpa antibodies and uses thereof
SA519410534B1 (ar) أجسام مضادة لعامل مساعد لموهن الخلايا الليمفاوية البائية والتائية واستخداماتها
EA201491411A1 (ru) Растворимый manf при поражениях бета-клеток поджелудочной железы
Mengel Deconstructing interstitial fibrosis and tubular atrophy: a step toward precision medicine in renal transplantation
BR112015021507A8 (pt) métodos e composições para o diagnóstico de pré-eclampsia em uma mulher grávida e kit de ensaio de diagnóstico
AR071885A1 (es) Proteinas de union al receptor de interleuquina 21
Dang-Trinh et al. Analyses of the expression, immunohistochemical properties and serodiagnostic potential of Schistosoma japonicum peroxiredoxin-4
Clarke et al. Heightened autoantibody immune response to citrullinated calreticulin in bronchiectasis: implications for rheumatoid arthritis